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The enteric nervous systemGlucagon-like peptide 2 [GLP-2] is a 33-amino acid peptide released from themucosal enteroendocrine L-cells of
the intestine. The actions of GLP-2 are transduced by the GLP-2 receptor [GLP-2R], which is localized in the
neurons of the enteric nervous system but not in the intestinal epithelium, indicating an indirect mechanism
of action. GLP-2 is well known for its trophic role within the intestine and interest in GLP-2 is now reviving
based on the approval of the GLP-2R agonist for treatment of short bowel syndrome [SBS]. Recently it also
seems to be involved in glucose homeostasis.
The aimof this review is to outline the importance of neuroendocrine peptides, speciﬁcally of GLP-2 in the enteric
modulation of the gastrointestinal function and to focus on new works in order to present an innovative picture
of GLP-2.
© 2014 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2. GLP-2 as a neuroendocrine signal from the gastrointestinal tract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
3. GLP-2 in the gastrointestinal function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
4. GLP-2 in the ENS during inﬂammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
5. An innovative picture of GLP-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91. Introduction
Most of the currently known gut hormones were discovered in the
1980s [1]. However, glucagon-like substances in extracts of intestinal
mucosa had already been described in 1948 [2]. Up to now hormones
continue to be intensely studied such as the products of proglucagnon
including glucagon, oxyntomodulin [OXM] and proglucagon derived
peptides 1 [GLP-1], and 2 [GLP-2]. [3]. Glucagon is a counter-
regulatory hormone to insulin and acts in response to hypoglycemia
while GLP-1 is a potent incretin hormone which also inhibits glucagon
secretion [3,4]. GLP-1, in addition to inducing the secretion of insulin,
has been shown to have biological effects on the gastrointestinalcnologie Biologiche, Chimiche e
iversità di Palermo, Viale delle
: +39 91 6577501.
sano).functions in both animals [5–7] and humans [8–10]. Glucagon and
GLP-1 have been studied more than OXM and GLP-2, probably because
of their role in the regulation of glucose homeostasis. Anyway, both
OXM and GLP-2 have interesting biology. OXM seems to be a dual
agonist of both the glucagon-like peptide-1 receptor (GLP1R) and the
glucagon receptor (GCGR) and is involved in energetic and glucose
metabolism. It lowers food intake, increases energy expenditure and
improves glucose metabolism [11]. However, the mechanisms of
actions are not fully understood and it is still unclear if additional
G- protein-coupled receptors are engaged in the lowering of body
weight and glucose as well as GCGR and GLP-1R. Thus, further studies
are required to completely understand the mechanism of action.
GLP-2 is well known for its trophic role within the intestine [12] and
interest in GLP-2 is now reviving, based on the approval of the GLP-2R
agonist for treatment of short bowel syndrome [SBS] [13]. Recently it
also seems to be involved in the maintaining of glucose homeostasis
[14,15]. However, GLP-2 plays a multifaceted role within the intestine
[16] and the overwhelming interest attracted by GLP-2 as a trophic
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gastrointestinal processes.
This review focuses on the recent insights into the action of GLP-2 in-
volving the enteric nervous system [ENS] in order to outline its impor-
tance in the neural modulation of the gastrointestinal function and to
present an innovative picture of GLP-2 after the approval, by the
European Medicines Agency and the US Food and Drug Administration,
of the GLP-2R agonist, teduglutide.
2. GLP-2 as a neuroendocrine signal from the gastrointestinal tract
GLP-2 belongs to the GI hormone class and more speciﬁcally it is a
33-amino acid peptide that is secreted following nutrient ingestion by
the intestinal endocrine L cell through the cleavage of proglucagon
prohormone convertase 1/3. The GLP-2 action is initiated by binding
to its speciﬁc receptor, the GLP-2R that belongs to the class of seven
transmembrane- G protein-coupled receptors [16] and determines the
activation of cAMP protein Kinase -dependent pathway [17]. However,
GLP-2R has the ability to couple to different G protein subunits and to
activatemultiple signalling pathways [18]. Studies using cells that natu-
rally express the receptor suggest that phosphatidylinositol 3-kinase-
γ[PI3Kγ] and subsequent Akt phosphorylation are the intracellular
pathways activated by GLP-2 [19,20]. The enteric nervous system
seems to be a key component in the GLP-2 action, and this was initially
evident for one of the GLP-2's main activities, namely its ability to
enhance intestinal epithelial growth. The enteric neurons express the
receptor [21–24] and the GLP-2R activation is able to stimulate gut
epithelial growth and repair. In fact, the signal is transduced by the
GLP-2R on enteric neurons and is then transmitted back to the
epithelium [23]. On the contrary, in a model of partial enteric nervous
deﬁcit, the glial cell line-derived neurotropic factor family receptor
alpha [2] [GFRα2] knockout mouse, the loss of GFRα2 did not affect
its trophic action [25], suggesting that a functional ENS is not essential
to preserve this activity. However, compensation in a transgenic
model is common. Thus, it may also be possible that compensatory
mechanisms are triggered.
The GLP-2R is expressed by myoﬁbroblasts [26] and it was hypoth-
esized that GLP-2 exerts its trophic actions indirectly through
myoﬁbroblasts as well. Indeed, GLP-2 signalling induces the release of
several growth factors such us insulin-like growth factor-1 and
keratinocyte growth factor, that are responsible for the proliferative ef-
fects of GLP-2.
3. GLP-2 in the gastrointestinal function
The presence of GLP-2R in the ENS [21–24] has suggested that some
of theGLP-2 actionswithin the gutmay not be direct in the regulation of
the gastrointestinal [GI] function.
Later studies have conﬁrmed that GLP-2 affects gut motor activity
throughmodulation of the ENS [27,28]with theﬁnal purpose of slowing
motility in order to contribute and promote intestinal absorption. In the
mouse small intestine GLP-2 reduces the spontaneous smooth muscle
activity by increasing nitric oxide releases [22] while in the colon,
where the GLP-2R is expressed and colocalized with acetylcholine -IR
neurons of the myenteric plexus, the peptide acts by slowing themotil-
ity through inhibition of acetylcholine release from enteric neurons [28]
suggesting a paracrine mechanism of action. A functional ENS seems to
be essential for the GLP-2 motor action. Therefore, in the model of par-
tial enteric nervous deﬁcit, the [GFRα2] knockoutmouse, GLP-2was not
able to inhibit GI transit [25].
In the mouse stomach, in vitro, the exogenous administration of
GLP-2 induces gastric relaxation by neural prejunctional release of vaso-
active intestinal polypeptide [VIP], leading to an increase in the stomach
capacity. The effect is conﬁned to the fundus [27]. The GLP-2 action on
gastric fundus seems particularly interesting because it could represent
a signalling of satiety which well ﬁts in with the ﬁnding that GLP-2 is achemical mediator inhibiting rodent feeding behaviour [29,30]. Thus, it
is likely that the GLP-2 ability to decrease gastric motility, apart from
delaying the ﬂow through the pylorus and prolonging the gastric
emptying time, may also be part of the premature inhibition of further
ingestion as it constitutes a prandial satiety signal. Gastric distension
inhibits food intake via vagal afferent neurons through mechanisms
independent of nutrient status and the GLP-2R is localized in the cell
bodies of vagal afferents in the nodose ganglion [31,32]. This idea is
also supported by theﬁnding that in pigs, GLP-2 is able to reduce the va-
gally induced antral motility [33]. However, its effect on gastric empty-
ing in humans appearsminimal [34]. Moreover, although the peripheral
administration of GLP-2 reduces short term food intake inmice [29], it is
still unclear if this effect can be related to its action within the GI tract.
By peripheral administration, the neuropeptides label the blood–brain
barrier-free area postrema and diffuse into the adjacent regions [35].
GLP-2R is expressed also in key regions of the brain including the
hypothalamus and the hippocampus [30,36]. In the hypothalamus the
activation of the GLP-2R reduces gastric emptying probably through
the melanocortin system [37].
It is interesting to note that diet induced obese mice are less sensitive
to the GLP-2mediated short term reduction of food intake [29]. They also
display increased levels of the plasma peptide [38] and of the GLP-2R ex-
pression in the stomach [39]. These results suggest that a deregulation of
the GLP-2/GLP-2R system following chronic high fat diet probably occurs.
The peptide also affects the secretory function of the GI tract. In
humans, GLP-2 is capable of inhibiting both pentagastrin-stimulated
and sham feeding-stimulated human gastric acid secretion [40,41],
likely counteracting the parasympathetic stimulation of the stomach.
In the guinea pig GLP-2 modulates enteric mucosal chloride secretion.
Speciﬁcally, in the small intestine GLP-2 acts on the GLP-2R, expressed
in the submucosal plexus, to suppress acetylcholine release. This action
of GLP-2 reduces the liquidity in the intestinal lumen by decreasing the
secretion of NaCl and H2O [21]. Thus, GLP-2 is likely to act in a paracrine
mode to inﬂuence intestinal function, via ENS and in a hormonal mode
to inﬂuence gastric function.
4. GLP-2 in the ENS during inﬂammation
GLP-2 protects the ENS duringmucosal inﬂammation [42,43]. Usually,
during intestinal inﬂammation there is a decrease in the numbers of
submucosal and myenteric neurons and changes to enteric glial cells
within the enteric ganglia. These acute changes in neuronal cell num-
bers are accompanied by changes in speciﬁc neuronal activity, including
the integrated motor and secretory functions of the intestine [44].
GLP-2 in this state is able to enhance survival of the enteric neurons
in culture and to counteract mast cell induced neuronal cell death
[45]. Moreover, in a culture of submucosal plexus neurons, GLP-2 is
able to inﬂuence the proﬁle of expression of the enteric neurons
[46]. This suggests that GLP-2-induced neuroprotection of enteric
neurons is mediated by direct stimulation of neuronal GLP-2R.
However, experimental evidence has led to the proposal that GLP-2
effects could involve different indirect mediators and diverse
signalling pathways [47]. One such mediator in both physiological and
inﬂammatory conditions is VIP [27,42,43]. GLP-2 reduces intestinal
mucosal inﬂammation by activation of VIP neurons in the submucosal
plexus independent of any proliferative effects [43]. It restores the
enteric neuronal populations to normal and inﬂuences the number
and proportion of VIP-expressing neuronswithin the colonic submucosal
plexus in vivo [42]. The GLP-2 ability to stimulate a neuronal phenotype,
increasing VIP expression in primary culture of cells deriving from the
submucosal plexus [46] has led to the idea that GLP-2 might also be
involved in regulating the development of the ENS. In fact, a high level
of expression of both hormone and receptor has been shown in the im-
mature gut of human infants and mouse models in the later phases of
gestation, when intestinal development is maximal [48,49]. Thus, it is
possible to speculate that a deﬁcit in GLP-2 production could be involved
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tive effects have also been demonstrated on hippocampal neurons [50].
Therefore, in consideration of the GLP-2 ability to promote survival in dif-
ferent types of neurons, the next step to propose is to test theGLP-2 effect
on a model of neurodegenerative diseases, such as Alzheimer disease.
Apart from GLP-2 protective action on the ENS during mucosal
inﬂammation, other studies have shown that GLP-2 is a protective sig-
nalling in other areas during inﬂammatory state. For example, chronic
GLP-2 treatment lowersmetabolic endotoxemia and hepatic inﬂamma-
tory tone in genetically obesemice. It reduces plasma LPS and decreases
levels of circulating proinﬂammatory cytokines as well as tissue
markers of oxidative stress and macrophage inﬂammation, while the
treatment with the GLP-2R antagonist, GLP-2 (3–33), exacerbates the
inﬂammatory condition [51].
5. An innovative picture of GLP-2
The scientiﬁc understanding of GLP-2 has highlighted its central role
as trophic regulator of mucosal function [12] and has led to the recent
approval by the European Medicines Agency and the U.S. Food and
Drug Administration of teduglutide, the long acting agonist of GLP-2
for the treatment of SBS [13]. This is providing patients with SBS with
an addition to the present limited treatment, currently consisting
mainly of anti-diarrhoeal and anti-secretory medications.
As GLP-2 is a potent and speciﬁc gastrointestinal growth factor, the
recent studies in the ﬁeld are looking further into the characterization
of its action in experimental settings reproducingdifferent intestinal pa-
thologies in different ages in which the intestinal pathologies occur.
Apart fromGLP-2 itself, studies are focusing on the effects of teduglutide
and of the inhibitor of its degradation, dipeptidyl peptidase-4.
Due to its action of enhancing cellular growth, one of the main con-
cerns is about the possibility that GLP-2 analoguemay also stimulate the
growth of malignant cells [52,53]. A study conducted in patients with
intestinal failure associated with short bowel syndrome showed that
6 months teduglutide treatment enhanced the structural adaptation of
the small intestinal mucosa without indications of dysplastic transfor-
mation [54]. Thus, this study encourages therapeutic use of the drug
to reduce dependence on parenteral nutrition without the risk of devel-
oping dysplasia although a 6 month course of treatment is a relatively
short time. Thus, long-term surveillance studies are needed to exclude
potential adverse outcomes.
Another issue is about the importance of characterizing the GLP-2
effects on intestinal pathologies in the early stages of life because a
number of these conditions occur in newborn babies and infants that
are very different from adults in their disposition and response to
drugs [55]. Moreover, it is imperative to verify if GLP-2 by stimulating
mucosal proliferation also encourages the growth of malignant cells in
children because they potentially might need the treatment over a lon-
ger period of time. Besides, in consideration of its effects as an anorectic
factor, in animal models [30,35], experiments to verify if at an early age
it affects appetite and/or behaviour are mandatory in order to guide the
correct development of therapeutic applications in the different stages
of life. A study about the therapeutic application of GLP-2 in early life
conducted on newborn pigs is encouraging. It showed that the exoge-
nous administration of GLP-2 stimulates small intestinal growth during
weaning in neonatal pigs without polyps or unusual growths in the in-
testine [56]. It is of interest to note that the authors administered a dose
of 40 μg/kg/day, in two subcutaneous injections a day, which is twice
that of a pharmacological dose of GLP-2 used in the majority of adult
human trials [57–60]. They reported that the effects were limited to
the gastrointestinal tract and it was well tolerated with no measurable
changes in activity, growth, development, renal and hepatic function,
or growth in non-gastrointestinal tissues [56]. Although this study is
quite promising, the relatively short period of treatment, 42 days,
should be considered and the potential side effects of prolonged treat-
ment explored.Another interesting study veriﬁed the potential applicability of
teduglutide in improving intestinal adaptation in paediatric patients
with short bowel syndrome. They used newborn piglet jejunostomy
models that mimic newborn human short bowel syndrome following
gut resection [61]. They reported that after 7 days of daily injections
with teduglutide (doses from 0.01 mg/Kg/day to 0.2 mg/Kg/day) the
trophicity of the intestine was increased but the effects on mucosal
function were limited. Indeed, teduglutide treatment did not increase
the activity of digestive enzymes and the absorption of enteral nutri-
ents. The study is a good starting point because it indicates that 7 days
of treatment in infants is sufﬁcient for intestinal morphological adapta-
tion but not enough to improve the gut function.
Although teduglutide has been approved by the EuropeanMedicine
and theU.S. Food andDrug Administration for the treatment of SBS [13],
and is in clinical trials for Crohn's Disease [62] studies with humans are
still limited. A study conducted in paediatric patients with acute ileal
Crohn disease (CD) reported reduction in postprandial GLP-2 release
with potential consequence on nutrient absorptive capacity [63]. Thus,
this study suggests that the inﬂammatory states reduce GLP-2 meal-
stimulated release. Unfortunately, the GLP-2 release mechanisms are
not fully understood and deserve further studies. What is known, is
that the stimulus for the early postprandial peak is neural mediated. In
fact, in rats, vagotomy prevents stimulation of L cells by fat, while direct
activation of the celiac branch of the vagus increases secretion [64]. The
direct contact of luminal nutrients with L cells induces the second peak
of GLP-2 secretion [65]. Over time it has been observed that patients
with intestinal inﬂammation have changes in the pattern of encoding
neurons [66,67] which may be signalled by a reduction in ongoing en-
dogenous GLP-2. Therefore, it is priority to fully elucidate the release
mechanism of native GLP-2 in order to optimize it.Moreover, it is essen-
tial to explore the inﬂuence of the modiﬁcation of the diet content on
GLP-2 secretion to see if and to what extent it is affected and to assess
its inﬂuence on the plasticity of ENS. Thismight be of interest for the de-
velopment of therapeutic strategies in patients who have acute inﬂam-
mation such as CD.
GLP-2 capacity to enhance barrier function is an interesting charac-
teristic because very few known drugs or therapies can reduce gut leak-
iness [68]. However, to improve its therapeutic application, the action
mechanism on barrier function should be fully elucidated. As the GLP-
2R does not localize to the target tissue such as crypt epithelium and
enterocytes [13] it requires mediators to exert its trophic actions. Re-
cently, the intestinal epithelial insulin like growth factor 1 receptor
(IE-IGF-1R) has been found to act as a mediator [69]. Indeed, 10 days
treatment of mice with 0.1 μg/g of h(Gly2)GLP-2, a pharmacological
dose of a degradation-resistant GLP-2 analogue, reduced the gastroin-
testinal permeability in control mice with increased expression of the
sealing proteins claudin-3 and 7 but not in IE-IGF-1R null mice strongly
suggesting its involvement in the GLP-2 action.
In the new picture of GLP-2 it is interesting to point out the involve-
ment of the neuroendocrine signal in the glucose homeostasis. Barhami
and Coll. reported that in genetically obese mice elimination of GLP-2R
signalling impaired the normal islet adaptative response required to
maintain glucose homeostasis [15] while the study of Shi and Coll.
[14] showed that the GLP-2R deletion in pro-opiomelanocortin
[POMC] neurons impairs postprandial glucose tolerance and hepatic in-
sulin sensitivity. These studies strongly suggest that endogenous GLP-2
is functionally important for glucose homeostasis although future stud-
ies, for example, using chronic treatment with the GLP-2R antagonist to
block the endogenous GLP-2 action instead of knockout models, that
could activate compensatory mechanism, are mandatory.
6. Conclusion
The study of GLP-2 has led to innovative treatment in conditions of
intestinal injury such as SBS. It can be considered as a unique
enteroendocrine hormone for its activity as a speciﬁc intestinal growth
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the gut that involves the ENS in the attempt to shed more light on the
link between GLP-2 and the activity and overall function of the ENS.
Moreover, we have pointed out what has been achieved following the
approval of teduglutide and what should be done in order to improve
its application. We have focused on ENS because we considered its
action potentially important in the regulation of the function in the GI
tract as well as the protective effects of GLP-2 on neuron growth and
phenotype. With the spread of gastrointestinal dysfunction on the rise,
to clarify these kinds of effects and to analyze the mechanism of action
and possible other interaction, it may be important to understand the
intestinal function better both at the physiological and the pathophysi-
ological states. Many questions remain to be answered and one of these
is whether the normal postprandial release of GLP-2 may signal a
physiological effect on enteric neuronal populations, as well as the
GLP-2 involvement in glucose homeostasis.Conﬂict of interest
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